Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07502872 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Study acronym: TPG
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 31 days later Dec 1, 2029 → Jan 1, 2030
See other at-risk trials from Brown University

Record History

  1. Start date: May 1, 2026 to Nov 1, 2026
    • Primary and study completion pushed from Dec 1, 2029 to Jan 1, 2030
    • Secondary endpoints: details revised at 3 of 8 entries
    • Site contact updated
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Brown University
80 trials monitored
See 9 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Trial Details
NCT Number NCT07502872
Lead Sponsor Brown University
Collaborators: Incyte Corporation, Genentech, Inc., Natera, Inc.
Conditions
(from sponsor)		 Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Related terms Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov